On January 5, 2026, ScinoPharm Taiwan Ltd. (TWSE: 1789), based in Tainan, announced a significant milestone: U.S. Food and Drug Administration (FDA) approval for its Glatiramer Acetate Injection, a therapeutic equivalent to Teva’s Copaxone® for the treatment of relapsing forms of multiple sclerosis (MS). This approval positions ScinoPharm as the only Taiwanese pharmaceutical company to successfully navigate the stringent regulatory pathway for this product, underscoring Taiwan’s emerging role in the global complex generics sector.
Multiple sclerosis affects nearly 1 million people in the United States and 2.9 million worldwide. Glatiramer acetate, first approved in 1996, is a cornerstone disease-modifying therapy that reduces relapse frequency by modulating immune responses believed to damage myelin in the central nervous system. The global market for glatiramer acetate was valued at USD 1.5 billion in 2024, with projections reaching USD 2.8 billion by 2033, and the U.S. segment alone estimated at around USD 700 million.
Glatiramer acetate presents exceptional development challenges as a Non-Biological Complex Drug (NBCD). Unlike traditional small-molecule generics, it is a heterogeneous mixture of synthetic polypeptide chains with varying lengths and sequences, lacking a fixed molecular structure or uniform weight. This complexity necessitates advanced characterization: ScinoPharm employed over 40 analytical techniques, statistical modeling, and biological activity assays to prove sameness and equivalence to the reference product. Manufacturing reproducibility and quality control demand precise control of polymerization parameters, a barrier that limits global producers to just a handful.
This achievement validates years of ScinoPharm’s investment in R&D, process development, and manufacturing capabilities for high-barrier complex generics. It not only enhances access to affordable MS treatment but also strengthens the company’s competitive standing against international leaders. Looking ahead, ScinoPharm is pursuing regulatory filings and partnerships in Europe, Asia, and emerging markets to broaden its footprint in generic finished dosage forms, building on its established strength in active pharmaceutical ingredients (APIs).
